BIOMARIN PHARMACEUTICAL INC (BMRN) Latest Company News

Sep 16, 2026, 17:05 UTC
BioMarin Pharmaceutical discontinued development of Voxzogo (vosoritide) for the treatment of Noonan syndrome.
Source:
- zacks.com
Sep 14, 2026, 13:32 UTC
BioMarin Pharmaceutical Inc appointed Robert Plenge as a member of its Board of Directors, effective September 10, 2026, with restricted stock units valued at $400,000 and a seat on the Science and Technology Committee.
Sep 9, 2026, 13:05 UTC
BioMarin announced positive Phase 3 results for VOXZOGO in hypochondroplasia, published in NEJM Evidence and presented at ESPE 2026, and recently submitted an sNDA to the FDA for expanded approval.
Source:
- prnewswire.com
Aug 31, 2026, 11:05 UTC
BioMarin Pharmaceutical signed a binding term sheet with Ascendis Pharma for a global settlement and license agreement, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to certain BioMarin patents for products including TransCon CNP, navepegritide, or Yuviwel, with all pending litigation to be dismissed with prejudice.
Source:
- s.kabutan.jp
- s.kabutan.jp
Aug 18, 2026, 00:00 UTC
BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics B.V. in a cash-free, debt-free share purchase transaction for an upfront $275 million cash payment plus up to $215 million in contingent development milestone payments, with closing expected in the third quarter of 2026.
Source:
Aug 12, 2026, 14:05 UTC
BioMarin Pharmaceutical announced plans to integrate Amicus Therapeutics as part of its rare-disease growth strategy, with a focus on faster deleveraging.
Source:
- marketbeat.com
Aug 6, 2026, 20:03 UTC
BioMarin reported second quarter 2026 financial results with total revenues of $990 million, up 20% year-over-year.
Source:
Jul 27, 2026, 13:05 UTC
BioMarin and n-Lorem Foundation entered a strategic collaboration and global exclusive license agreement to develop an antisense oligonucleotide medicine for ReNU syndrome.
Source:
- prnewswire.com
Jul 14, 2026, 15:46 UTC
The FDA accepted BioMarin's supplemental New Drug Application seeking full approval for Voxzogo in achondroplasia.
Source:
- zacks.com
- prnewswire.com
Jun 4, 2026, 00:00 UTC
BioMarin Pharmaceutical Inc. elected Elizabeth M. Anderson, Barbara W. Bodem, Ian T. Clark, Athena Countouriotis, and Willard Dere as directors, effective June 2, 2026.

BMRN

BioMarin Pharmaceutical discontinued development of Voxzogo (vosoritide) for the treatment of Noonan syndrome.

BioMarin Pharmaceutical Inc appointed Robert Plenge as a member of its Board of Directors, effective September 10, 2026, with restricted stock units valued at $400,000 and a seat on the Science and Technology Committee.

BioMarin announced positive Phase 3 results for VOXZOGO in hypochondroplasia, published in NEJM Evidence and presented at ESPE 2026, and recently submitted an sNDA to the FDA for expanded approval.

BioMarin Pharmaceutical Inc. agreed to acquire Alesta Therapeutics B.V. in a cash-free, debt-free share purchase transaction for an upfront $275 million cash payment plus up to $215 million in contingent development milestone payments, with closing expected in the third quarter of 2026.

BioMarin Pharmaceutical announced plans to integrate Amicus Therapeutics as part of its rare-disease growth strategy, with a focus on faster deleveraging.

BioMarin reported second quarter 2026 financial results with total revenues of $990 million, up 20% year-over-year.

BioMarin and n-Lorem Foundation entered a strategic collaboration and global exclusive license agreement to develop an antisense oligonucleotide medicine for ReNU syndrome.

The FDA accepted BioMarin's supplemental New Drug Application seeking full approval for Voxzogo in achondroplasia.

BioMarin Pharmaceutical Inc. elected Elizabeth M. Anderson, Barbara W. Bodem, Ian T. Clark, Athena Countouriotis, and Willard Dere as directors, effective June 2, 2026.